RXK3 Stock Overview
A late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
SELLAS Life Sciences Group, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.56 |
| 52 Week High | US$1.79 |
| 52 Week Low | US$0.80 |
| Beta | 2.35 |
| 1 Month Change | 35.29% |
| 3 Month Change | 31.87% |
| 1 Year Change | 16.37% |
| 3 Year Change | -46.36% |
| 5 Year Change | -53.13% |
| Change since IPO | -99.44% |
Recent News & Updates
Recent updates
Shareholder Returns
| RXK3 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 24.1% | -0.5% | 1.1% |
| 1Y | 16.4% | -13.0% | 16.0% |
Return vs Industry: RXK3 exceeded the German Biotechs industry which returned -13.5% over the past year.
Return vs Market: RXK3 exceeded the German Market which returned 15% over the past year.
Price Volatility
| RXK3 volatility | |
|---|---|
| RXK3 Average Weekly Movement | 14.2% |
| Biotechs Industry Average Movement | 5.8% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in DE Market | 12.8% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: RXK3's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: RXK3's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 15 | Angelos Stergiou | www.sellaslifesciences.com |
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company’s lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009.
SELLAS Life Sciences Group, Inc. Fundamentals Summary
| RXK3 fundamental statistics | |
|---|---|
| Market cap | €140.94m |
| Earnings (TTM) | -€24.05m |
| Revenue (TTM) | n/a |
Is RXK3 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RXK3 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$27.13m |
| Earnings | -US$27.13m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.30 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did RXK3 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/20 20:20 |
| End of Day Share Price | 2025/05/20 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
SELLAS Life Sciences Group, Inc. is covered by 5 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| James Molloy | Alliance Global Partners |
| Joseph Pantginis | H.C. Wainwright & Co. |
| Aydin Huseynov | Ladenburg Thalmann & Company |